실제임상증거(RWE) 시장 예측(2034년) : 구성요소, 데이터 소스, 치료 영역, 도입 형태, 분석 방법, 연구 유형, 데이터 처리 방법, 용도, 최종사용자 및 지역별 분석

According to Stratistics MRC, the Global Real-World Evidence Market is accounted for $6.3 billion in 2026 and is expected to reach $20.9 billion by 2034 growing at a CAGR of 16.1% during the forecast period. The Real-World Evidence Market is growing because healthcare providers and life science companies increasingly use everyday clinical data to understand how treatments perform in real settings. Information from electronic records, insurance claims, patient registries, wearable devices, and reported outcomes supports better decisions on safety, effectiveness, and healthcare spending. Pharmaceutical firms, insurers, and regulators depend on this evidence for research, approval support, reimbursement decisions, and ongoing product monitoring. Rising interest in personalized care, outcomes-based models, and data-led healthcare is strengthening demand worldwide, while improvements in artificial intelligence, analytics, and data integration are making real-world evidence more reliable and valuable for stakeholders.

Market Dynamics:

Driver:

Increasing Use of Electronic Health Records and Healthcare Data Sources

Growing adoption of electronic medical records, insurance data, registries, and digital healthcare technologies is accelerating the Real-World Evidence Market. These sources generate valuable information related to patient demographics, treatment outcomes, healthcare utilization, and disease trends. Healthcare companies and researchers are increasingly analyzing large datasets to support clinical studies, regulatory requirements, and strategic healthcare decisions. Worldwide digital transformation in healthcare is enhancing the collection, management, and availability of real-world information. As organizations look beyond conventional clinical trial results to understand real-life treatment performance, advanced platforms for collecting and analyzing real-world evidence are becoming increasingly important across the healthcare ecosystem.

Restraint:

High Costs Associated with Real-World Evidence Data Management and Analytics

High implementation and operational costs are major restraints affecting the growth of the Real-World Evidence Market. Developing effective real-world evidence solutions requires significant investments in data acquisition, advanced analytics platforms, artificial intelligence tools, cloud infrastructure, and skilled personnel. Healthcare organizations must allocate resources for data integration, quality management, cybersecurity, and regulatory compliance activities. These expenses can create financial challenges, particularly for smaller organizations and research institutions with limited budgets. Additionally, maintaining large-scale real-world data ecosystems requires continuous investment and technological upgrades. The high cost burden may slow adoption and restrict access to advanced real-world evidence capabilities.

Opportunity:

Expansion of Real-World Evidence Adoption in Emerging Healthcare Markets

The increasing adoption of real-world evidence solutions across emerging healthcare markets represents a major opportunity for market expansion. Developing regions are experiencing improvements in healthcare infrastructure, digital transformation, and data availability, creating favorable conditions for real-world evidence implementation. Governments, healthcare providers, and research organizations are increasingly focusing on data-driven healthcare strategies to improve disease management and clinical outcomes. The expansion of electronic health records, healthcare databases, and digital platforms in these regions will support broader evidence generation capabilities. As awareness and investment increase, emerging markets are expected to provide significant growth opportunities for real-world evidence providers and technology companies.

Threat:

Data Fragmentation and Interoperability Challenges Across Healthcare Systems

Fragmented healthcare data ecosystems and limited interoperability between different healthcare systems create threats to the growth of the Real-World Evidence Market. Real-world evidence depends on integrating information from multiple sources, including hospitals, insurance providers, patient registries, and digital health platforms. Differences in data formats, infrastructure, and information-sharing standards can make seamless integration difficult. These challenges may reduce data accessibility, affect evidence quality, and increase the complexity of analytics processes. Healthcare organizations require standardized frameworks and improved interoperability solutions to overcome these limitations. Persistent fragmentation issues could slow the adoption of real-world evidence platforms and restrict their ability to deliver comprehensive healthcare insights.

Covid-19 Impact:

The COVID-19 outbreak accelerated the expansion of the Real-World Evidence Market by highlighting the importance of real-time healthcare insights and data-driven clinical decisions. The urgent need to evaluate therapies, vaccines, and patient outcomes encouraged greater adoption of real-world evidence solutions among life science companies and healthcare institutions. Increased reliance on telehealth services, digital healthcare technologies, and remote monitoring systems generated additional data sources for evidence generation. While the pandemic created significant opportunities for market development, organizations also faced difficulties related to data integration, regulatory requirements, and maintaining reliable information quality. Overall, COVID-19 acted as a catalyst for advancing real-world evidence applications in healthcare.

The RWE Analytics Platforms segment is expected to be the largest during the forecast period

The RWE Analytics Platforms segment is expected to account for the largest market share during the forecast period, due to the increasing demand for advanced technologies that can efficiently process, integrate, and analyze complex healthcare datasets. These platforms enable pharmaceutical companies, healthcare providers, and research organizations to generate actionable insights from diverse real-world data sources. The growing adoption of artificial intelligence, machine learning, and predictive analytics is further strengthening the importance of analytics platforms in evidence generation. Their ability to improve clinical decision-making, optimize research processes, and support regulatory requirements makes them a critical component driving market growth.

The Clinical Decision Support segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Clinical Decision Support segment is predicted to witness the highest growth rate, due to the growing adoption of data-driven healthcare solutions that assist physicians in making accurate and personalized treatment decisions. Real-world evidence enables healthcare providers to analyze patient histories, treatment outcomes, and clinical patterns to improve diagnosis and care delivery. The increasing integration of artificial intelligence, electronic health records, and predictive analytics is accelerating the adoption of clinical decision support systems. These solutions help enhance patient outcomes, reduce healthcare costs, and support value-based care models, driving rapid growth within the real-world evidence ecosystem.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, because of its well-established healthcare ecosystem, advanced data management capabilities, and high adoption of innovative healthcare technologies. The region benefits from the presence of major life science companies and research organizations that increasingly rely on real-world evidence for clinical studies, safety monitoring, and regulatory support. The expansion of digital health systems, electronic medical records, and analytics-driven healthcare approaches is further supporting market growth. Rising investments in precision medicine and evidence-based healthcare strategies continue to enhance the demand for real-world evidence solutions throughout North America.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR in the Real-World Evidence Market as healthcare systems across the region increasingly embrace digital technologies and data-driven decision-making approaches. Expanding healthcare facilities, rising investments in healthcare IT infrastructure, and greater utilization of advanced analytics are supporting the adoption of real-world evidence platforms. The growing presence of pharmaceutical research activities, clinical trials, and precision healthcare initiatives is contributing to market expansion. Furthermore, improving data accessibility, evolving regulatory environments, and increasing awareness of evidence-based healthcare practices are expected to accelerate the demand for real-world evidence solutions throughout the Asia-Pacific region.

Key players in the market

Some of the key players in Real-World Evidence Market include IQVIA Holdings Inc., ICON plc, Parexel International Corporation, Thermo Fisher Scientific Inc., Oracle Corporation, Veeva Systems Inc., Veradigm LLC, Optum Inc., Flatiron Health Inc., Aetion Inc., TriNetX LLC, ConcertAI LLC, Datavant Inc., Tempus AI Inc., Cegedim Health Data, SAS Institute Inc., Komodo Health Inc. and Evidation Health Inc.

Key Developments:

In June 2026, ICON plc partnered with Advarra in March 2026 to develop a connected site network model. The collaboration integrates clinical research technologies and site-focused systems to improve study execution, data connectivity, and operational efficiency, supporting broader evidence-generation activities across clinical research environments.

In August 2025, IQVIA and Veeva announced global clinical and commercial partnerships in August 2025. The agreement enables customers to use IQVIA and Veeva software, data, technology, and service offerings together.

Components Covered:

• Data Sets
• RWE Analytics Platforms
• Services

Data Sources Covered:

• Electronic Health Records (EHRs)
• Electronic Medical Records (EMRs)
• Claims and Billing Data
• Pharmacy Data
• Clinical Trial Data
• Patient-Generated Health Data (PGHD)
• Wearable and Digital Health Device Data
• Disease Registries
• Health Surveys and Patient-Reported Data
• Social Media and Online Health Data

Therapeutic Areas Covered:

• Oncology
• Cardiovascular Diseases
• Neurology
• Immunology and Autoimmune Diseases
• Respiratory Diseases
• Infectious Diseases
• Diabetes and Metabolic Disorders
• Rare Diseases
• Gastrointestinal Diseases
• Ophthalmology
• Other Therapeutic Areas

Deployment Modes Covered:

• Cloud-Based
• On-Premises
• Hybrid

Analytics Types Covered:

• Descriptive Analytics
• Predictive Analytics
• Prescriptive Analytics
• Artificial Intelligence (AI)-Based Analytics
• Machine Learning-Based Analytics

Study Types Covered:

• Retrospective Studies
• Prospective Studies
• Observational Studies
• Longitudinal Studies
• Pragmatic Clinical Trials
• Comparative Effectiveness Studies

Data Processing Approachs Covered:

• Structured Data Analysis
• Unstructured Data Analysis
• Natural Language Processing (NLP)-Based Analysis
• Real-Time Data Processing

Applications Covered:

• Drug Development and Clinical Research
• Regulatory Decision-Making
• Market Access and Reimbursement
• Pharmacovigilance and Drug Safety Monitoring
• Comparative Effectiveness Research
• Healthcare Quality Improvement
• Disease Epidemiology and Burden Analysis
• Clinical Decision Support
• Population Health Management

End Users Covered:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Healthcare Providers
• Academic and Research Institutions
• Government and Regulatory Agencies
• Health Insurance Providers and Payers
• Medical Device Companies

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Real-World Evidence Market, By Component

• 5.1 Data Sets
• 5.2 RWE Analytics Platforms
• 5.3 Services

6 Global Real-World Evidence Market, By Data Source

• 6.1 Electronic Health Records (EHRs)
• 6.2 Electronic Medical Records (EMRs)
• 6.3 Claims and Billing Data
• 6.4 Pharmacy Data
• 6.5 Clinical Trial Data
• 6.6 Patient-Generated Health Data (PGHD)
• 6.7 Wearable and Digital Health Device Data
• 6.8 Disease Registries
• 6.9 Health Surveys and Patient-Reported Data
• 6.10 Social Media and Online Health Data

7 Global Real-World Evidence Market, By Therapeutic Area

• 7.1 Oncology
• 7.2 Cardiovascular Diseases
• 7.3 Neurology
• 7.4 Immunology and Autoimmune Diseases
• 7.5 Respiratory Diseases
• 7.6 Infectious Diseases
• 7.7 Diabetes and Metabolic Disorders
• 7.8 Rare Diseases
• 7.9 Gastrointestinal Diseases
• 7.10 Ophthalmology
• 7.11 Other Therapeutic Areas

8 Global Real-World Evidence Market, By Deployment Mode

• 8.1 Cloud-Based
• 8.2 On-Premises
• 8.3 Hybrid

9 Global Real-World Evidence Market, By Analytics Type

• 9.1 Descriptive Analytics
• 9.2 Predictive Analytics
• 9.3 Prescriptive Analytics
• 9.4 Artificial Intelligence (AI)-Based Analytics
• 9.5 Machine Learning-Based Analytics

10 Global Real-World Evidence Market, By Study Type

• 10.1 Retrospective Studies
• 10.2 Prospective Studies
• 10.3 Observational Studies
• 10.4 Longitudinal Studies
• 10.5 Pragmatic Clinical Trials
• 10.6 Comparative Effectiveness Studies

11 Global Real-World Evidence Market, By Data Processing Approach

• 11.1 Structured Data Analysis
• 11.2 Unstructured Data Analysis
• 11.3 Natural Language Processing (NLP)-Based Analysis
• 11.4 Real-Time Data Processing

12 Global Real-World Evidence Market, By Application

• 12.1 Drug Development and Clinical Research
• 12.2 Regulatory Decision-Making
• 12.3 Market Access and Reimbursement
• 12.4 Pharmacovigilance and Drug Safety Monitoring
• 12.5 Comparative Effectiveness Research
• 12.6 Healthcare Quality Improvement
• 12.7 Disease Epidemiology and Burden Analysis
• 12.8 Clinical Decision Support
• 12.9 Population Health Management

13 Global Real-World Evidence Market, By End User

• 13.1 Pharmaceutical and Biotechnology Companies
• 13.2 Contract Research Organizations (CROs)
• 13.3 Healthcare Providers
• 13.4 Academic and Research Institutions
• 13.5 Government and Regulatory Agencies
• 13.6 Health Insurance Providers and Payers
• 13.7 Medical Device Companies

14 Global Real-World Evidence Market, By Geography

• 14.1 North America
  • 14.1.1 United States
  • 14.1.2 Canada
  • 14.1.3 Mexico
• 14.2 Europe
  • 14.2.1 United Kingdom
  • 14.2.2 Germany
  • 14.2.3 France
  • 14.2.4 Italy
  • 14.2.5 Spain
  • 14.2.6 Netherlands
  • 14.2.7 Belgium
  • 14.2.8 Sweden
  • 14.2.9 Switzerland
  • 14.2.10 Poland
  • 14.2.11 Rest of Europe
• 14.3 Asia Pacific
  • 14.3.1 China
  • 14.3.2 Japan
  • 14.3.3 India
  • 14.3.4 South Korea
  • 14.3.5 Australia
  • 14.3.6 Indonesia
  • 14.3.7 Thailand
  • 14.3.8 Malaysia
  • 14.3.9 Singapore
  • 14.3.10 Vietnam
  • 14.3.11 Rest of Asia Pacific
• 14.4 South America
  • 14.4.1 Brazil
  • 14.4.2 Argentina
  • 14.4.3 Colombia
  • 14.4.4 Chile
  • 14.4.5 Peru
  • 14.4.6 Rest of South America
• 14.5 Rest of the World (RoW)
  • 14.5.1 Middle East
    • 14.5.1.1 Saudi Arabia
    • 14.5.1.2 United Arab Emirates
    • 14.5.1.3 Qatar
    • 14.5.1.4 Israel
    • 14.5.1.5 Rest of Middle East
  • 14.5.2 Africa
    • 14.5.2.1 South Africa
    • 14.5.2.2 Egypt
    • 14.5.2.3 Morocco
    • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

• 15.1 Industry Value Network and Supply Chain Assessment
• 15.2 White-Space and Opportunity Mapping
• 15.3 Product Evolution and Market Life Cycle Analysis
• 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

• 16.1 Mergers and Acquisitions
• 16.2 Partnerships, Alliances, and Joint Ventures
• 16.3 New Product Launches and Certifications
• 16.4 Capacity Expansion and Investments
• 16.5 Other Strategic Initiatives

17 Company Profiles

• 17.1 IQVIA Holdings Inc.
• 17.2 ICON plc
• 17.3 Parexel International Corporation
• 17.4 Thermo Fisher Scientific Inc.
• 17.5 Oracle Corporation
• 17.6 Veeva Systems Inc.
• 17.7 Veradigm LLC
• 17.8 Optum Inc.
• 17.9 Flatiron Health Inc.
• 17.10 Aetion Inc.
• 17.11 TriNetX LLC
• 17.12 ConcertAI LLC
• 17.13 Datavant Inc.
• 17.14 Tempus AI Inc.
• 17.15 Cegedim Health Data
• 17.16 SAS Institute Inc.
• 17.17 Komodo Health Inc.
• 17.18 Evidation Health Inc.